Sequential activation and production of matrix metalloproteinase-2 during breast cancer progression

Clinical and Experimental Metastasis

Volumn 14, Issue 6, 1996, Pages 512-519

  Lee, Kyong Sik ^a   Rha, Sun Young ^a   Kim, Sea Joong ^a   Kim, Joo Hang ^a   Roh, Jae Kyung ^a   Kim, Byung Soo ^a   Chung, Hyun Cheol ^a  

^a Yonsei University College of Medicine   (South Korea)

Author keywords

activation ratio; activity; breast cancer; MMP 2

Indexed keywords

GELATINASE A; MATRIX METALLOPROTEINASE; TUMOR MARKER;

ARTICLE; BREAST CANCER; CANCER INVASION; CONTROLLED STUDY; ENZYME ACTIVITY; HUMAN; HUMAN CELL; HUMAN TISSUE; METASTASIS; PROGNOSIS; PROTEIN EXPRESSION;

BREAST; BREAST DISEASES; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; DISEASE PROGRESSION; ENZYME ACTIVATION; FEMALE; GELATINASES; HUMANS; MATRIX METALLOPROTEINASE 2; METALLOENDOPEPTIDASES; NEOPLASM PROTEINS; PROGNOSIS;

EID: 0030472720     PISSN: 02620898     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF00115111     Document Type: Article

References (35)

1. Stetler-Stevenson WG, 1990, Type IV collagenases in tumor invasion and metastasis. Cancer Metast Rev, 9, 289-303.
2. Tryggvason K, Hoyhtya M and Pyke C, 1993, Type IV collagenases in invasive tumors. Breast Cancer Res Treat, 24, 209-18.
3. Stetler-Stevenson WG, Krutzsch HC, Wacher MP, Marguiles IMK and Liotta LA, 1989, The activation of human type IV collagenase proenzyme. Sequence identification of the major conversion product following organomercurial activation. J Biol Chem, 264, 1353-6.
4. Thompson EW, Paik SM, Brunner N, et al. 1992, Association of increased basement membrane invasiveness with absence of estrogen receptor and expression of vimentin in human breast cancer cell lines. J Cell Physiol, 150, 534-44.
5. Azzam HS, Arand GA, Lippman ME and Thompson EW, 1993, MMP-2 activation potential associates with metastatic progression in human breast cancer cell lines, and is independent of MMP-2 production. J Natl Cancer Inst, 85, 1758-64.
6. Sato H, Takino T, Okada Y, et al. 1994, A matrix-metalloproteinase expressed on the surface of invasive tumor cells. Nature, 370, 61-5.
7. Okada A, Belloco JP, Rouyer N, et al. 1994, Membrane-type matrix metalloproteinase (MT-MMP) gene is expressed in stromal cells of human colon, breast, and head and neck carcinomas. Proc Natl Acad Sci USA, 92, 2730-4.
8. Nomura H, Sato H, Seiki M, Masayoshi M and Okada Y, 1995, Expression of membrane-type matrix metalloproteinase in human gastric carcinomas. Cancer Res, 55, 3263-6.
9. Yu M, Sato H, Seiki M and Thompson EW, 1995, Complex regulation of MT-MMP expression and MMP-2 activation by concanavalin A in MDA-MB-231 human breast cancer cells. Cancer Res, 55, 3272-7.
10. Garbisa S, Negro A, Kalbic T, et al. 1988, Type IV collagenolytic activity linkage with the metastatic phenotype induced by ras transfection. Adv Exp Med Biol, 233, 179-86.
11. Nakajima M, Welch DR, Wynn DM, Tsuruo T and Nicolson GL, 1993, Serum and plasma Mr 92,000 progelatinase levels correlate with spontaneous metastasis of rat 13762NF mammary adenocarcinoma. Cancer Res, 53, 5802-7.
12. Naito K, Kanbayashi N, Nakajima S, Murai T, Arakawa K, Nishimura S and Okuyama A, 1994, Inhibition of growth of human tumor cells in nude mice by a metalloproteinase inhibitor. Int J Cancer, 58, 730-5.
13. Taraboletti G, Garofalo A, Belotti D, et al. 1995, Inhibition of angiogenesis and murine hemangioma growth by batimastat, a synthetic inhibitor of matrix metalloproteinases. J Natl Cancer Inst, 87, 293-8.
14. Alexander CM and Werb E, 1992, Targeted disruption of the tissue inhibitor of metalloproteinases gene increases the invasive behavior of primitive mesenchymal cells derived from embryonic stem cells in vitro. J Cell Biol, 118, 727-39.
15. DeClark YA, Yean TD, Lu HS, Ting J and Langley KE, 1991, Inhibition of autoproteolytic activation of interstitial procollagenase by recombinant metalloproteinase inhibitor MI/TIMP-2. J Biol Chem, 266, 3893-9.
16. DeClark YA, Perez N, Shimada H, Boone TC, Langley KE and Taylor SM, 1992, Inhibition of invasion and metastasis in cells transfected with an inhibitor of metalloproteinases. Cancer Res, 52, 701-7.
17. Reponen P, Sahlberg C, Huhtala P, Hurskainen T, Thesleff I and Tryggvason K, 1992, Molecular cloning of murine 70-kD type IV collagenase and its expression during mouse development. J Biol Chem, 267, 7856-62.
18. Pyke C, Ralkiaer E, Huhtala P, Hurskainen T, Dano K and Tryggvason K, 1992, Localization of messenger RNA for Mr 72,000 and 92,000 type IV collagenases in human skin cancers by in situ hybridization. Cancer Res, 52, 1336-41.
19. Pyke, C, Ralfkiaer E, Tryggvason K and Dano K, 1993, Messenger RNA for two type IV collagenases is located in non-malignant stromal cells in human colon cancer. Am J Pathol, 142, 359-65.
20. Levy AT, Cioce V, Sobel ME, et al. 1991. Increased expression of the Mr 72,000 type IV collagenase in human colonie adenocarcinoma. Cancer Res, 51, 439-44.
21. Boag AH and Young ID, 1994, Increased expression of the 72-kD type IV collagenase in prostatic adenocarcinoma. Demonstration by immunohistochemistry and in situ hybridization. Am J Pathol, 144, 585-91.
22. Stearns ME and Wang M, 1993, Type IV collagenase (Mr 72,000) expression in human prostate: benign and malignant tissue. Cancer Res, 53, 878-83.
23. Monteagudo C, Merino MJ, San-Juan J, Liotta LA and Stetler-Stevenson WG, 1990. Immunohistochemical distribution and type IV collagenase in normal, benign, and malignant breast tissue. Am J Pathol, 136, 585-92.
24. Polette M, Clavel C, Cockett M, Girod de Bentzmann S. Murphy and Birembaut P, 1993. Detection and localization of mRNAs encoding matrix metalloproteinases and their tissue inhibitor in human breast pathology. Invasion and Metastasis, 13, 31-7.
25. Davies B, Waxman J, Wasan H, et al. 1993, Levels of matrix metalloproteases in bladder cancer correlate with tumor grade and invasion. Cancer Res, 53, 5365-9.
26. David L, Nesland JM, Holm R and Sobrinho-Simoes M, 1994, Expression of laminin, collagen IV, fibronectin, and type IV collagenase in gastric carcinoma. Cancer, 73, 518-27.
27. Daidone MG, Silvestrini R, D'Errico A, et al. 1991, Laminin receptors, collagenase IV and prognosis in node negative breast cancers. Int J Cancer, 48, 529-32.
28. Heussen C and Dowdle EB, 1980, Electrophoretic analysis of plasminogen activators in polyacrylamide gel containing sodium dodecyl sulphate and co-polymerized substrates. Analyt Biochem, 102, 196-202.
29. Beahrs OH and Meyers MH, 1992, Manual for Staging of Cancer, 4th edn. Philadelphia: Lippincott.
30. Doussal VL, Tubiana-Hulin M, Friedman S, Hacerne K, Spyratos F and Brunei M, 1989. Prognostic value of histologic grade nuclear components of Scarff-Bloom-Richardson (SBR): an improved score modification based on a multivariate analysis of 1262 invasive ductal breast carcinomas. Cancer, 64, 1914-22.
31. Yates F, 1956, Analysis of contingency tables with grouping based on quantitative characters. Biometrika, 35, 176-81.
32. Brown PD, Bloxidge RE, Anderson E and Howell A, 1993, Expression of activated gelatinase in human invasive breast carcinoma. Clin Exp Metastasis, 11, 183-9.
33. Davies B, Miles DW, Happerfield LC, et al. 1993, L-myc, et al. 1993. Activity of type IV collagenases in benign and malignant breast disease. Br J Cancer, 67, 1126-31.
34. Brown PD, Bloxidge RE, Stuart NSA, Gatter KC and Carmichael J, 1993. Association between expression of activated 72-kilodalton gelatinase and tumor spread in non-small-cell lung carcinoma. J Natl Cancer Inst, 87, 574-8.
35. Kleiner DE and Stetler-Stevenson WG, 1994, Quantitative zymography: detection of picogram quantities of gelatinase. Analyt Biochem, 218, 325-9.